Suicide Risk Factors in Patients with Genitourinary Malignancies
the Cancer Therapy Advisor take:
Patients with genitourinary tumors, especially men, the elderly, and those with aggressive disease, are exposed to an increased number of suicide risk factors, according to an article published online in Cancer.
The study identified patients with prostate, bladder, kidney, testis, and penile cancer through the Surveillance, Epidemiology, and End Results database (1988-2012). Odd ratios (ORs) were also calculated to determine associated suicide factors for each type of cancer.
Out of the 1,239,522 patients with genitourinary malignancies, 2,268 suicides were noted. The calculated standardized mortality ratio (SMR) for patients was 1.37 for prostate cancer (0.99-1.86), 2.71 for bladder cancer (2.02-3.62), 1.86 for kidney cancer (1.32-2.62), 1.23 for testis cancer (0.88-1.73), and 0.95 for penile cancer (0.65-1.35), each with a 95% confidence interval.
ORs were calculated for the association of male sex and suicide risk for patients with bladder and kidney cancer (6.63 and 4.98, respectively). For elderly patients with prostate, bladder, and testis cancer, their increasing age was also associated with suicide (OR range, 1.03-1.06).
The researchers concluded that African American patients with prostate, bladder, and kidney cancer were less likely to commit suicide than their male counterparts (OR range, 0.26-0.46).
The study suggests that clinicians be increasingly aware of the suicide risk in patients with genitourinary malignancies.
Patients with genitourinary tumors are exposed to an increased number of suicide risk factors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia